Organovo (ONVO) Holdings announced that Eli Lilly (LLY) and Company will acquire Organovo’s FXR program, including its lead asset, FXR314. Under this transaction, Organovo will receive an ...

Following the announcement, shares in Organovo were trading a hefty 270% higher by lunchtime Tuesday. The deal will see Lilly acquire Organovo’s FXR program, including its lead asset, FXR314. All the ...

Smurfit Westrock PLC $44.21-1.50-3.28% ...

Objective Dysregulated cellular metabolism is a distinct hallmark of human colorectal cancer (CRC). However, metabolic programme rewiring during tumour progression has yet to be fully understood.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...